Daily Tech Briefing
AI 科技速览

每天 5 分钟内学习 AI。获取最新的人工智能新闻,理解其重要性,并学习如何将其应用于您的工作。

AI 快讯
arXiv Machine Learning · 2026/8/4 12:58:17

Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents

AI 中文解读
核心亮点:这项研究首次让AI学会像资深医药顾问一样,自主规划癌症药物的临床试验方案,且效果远超通用大模型。 通俗解读:开发新药就像走迷宫,每一步选错都可能浪费数年时间和数十亿资金。过去这全靠人类专家经验,现在科学家尝试用AI来“学习”历史成功案例。他们整理了3.1万份公开记录,包括临床试验注册、药企财报、流行病学数据等,让AI从45个真实药物项目中“观摩”决策过程。训练出的AI能根据当前信息,预测未来半年该推进哪些试验。结果显示,用“奖励加权模仿学习”方法训练的AI,在判断适应症上的准确率达到46%,而通用AI工具只有25%,尤其在2025年后的新数据上优势更明显。 实际影响:虽然这主要影响医药行业,但最终会惠及普通人。如果AI能更精准地规划试验,新药研发周期可能缩短、成本下降,意味着患者能更快用上便宜的新疗法,尤其是癌症等疑难重症。同时,这套“离线学习”方法也能迁移到其他高风险决策领域,比如金融投资或企业战略规划,让AI在数据有限时也能做出更靠谱的决策。
Clinical development is sequential decision-making under uncertainty, where a sponsor must plan a portfolio of experiments from heterogeneous evidence. We study this setting by framing oncology clinical development as an offline decision-making problem in which an agent predicts the next six-month trial portfolio of an oncology drug program from information available at the decision date. To support this, we construct a temporal dataset that combines 31.7k heterogeneous public data records, including trial registries, regulatory reviews, sponsor filings, utilization data, and epidemiology, into 881 offline decision episodes across 45 historical programs. We compare four offline objectives: behavioral cloning, reward-weighted behavioral cloning, learned-reward training, and value-based implicit Q-learning against four frontier LLM agents that share a common date-gated retrieval scaffold across held-out drug, sponsor, drug-class, and temporal splits. Models trained offline outperform the non-fine-tuned baselines, particularly in the post-August 2025 contamination-clean holdout. Reward-weighted behavioral cloning performs the best, obtaining 46.2% indication F1 and 14.2% strict F1 against 25.0% and 2.1%, respectively, for the best-performing tool agent on each metric. These results suggest that structured offline learning can teach agents to plan clinical experiments.
分享
阅读原文